Amaliris Guerra: Driving True Innovation in Preclinical Drug Development Related to Iron-Metabolism and Inflammation is One of My Passions!
Amaliris Guerra, Research Scientist at Children’s Hospital of Philadelphia, shared on LinkedIn:
”Driving true innovation in preclinical drug development related to iron-metabolism and inflammation is one of my passions!
Using a systems approach, I am always striving to find non-derivative approaches to advance therapeutic pipelines.
Recently, I launched Integrity Science Support LLC, a consulting company focusing on designing and supporting studies that creatively bridge basic scientific discovery into sound clinical translation.
I am seeking to collaborate with biotech and industry leaders on pre-IND studies, leveraging extensive experience in mouse models, iron metabolism, gene therapy, and the design and analysis of combination therapies.
Over a decade, I have led and supported projects that have resulted in patented gene therapy platforms, advanced TGF-beta ligand trap therapeutics (including luspatercept analogs and their combinations), and pioneered new approaches to study iron distribution and transferrin biology in both erythropoiesis and immune regulation.
My latest work, published in Blood (PMID: 40512402), demonstrates how TNFα signaling restores steady-state hematopoiesis following inflammatory insult, underscoring the anti-inflammatory therapeutic potential of TNFα and highlighting important inflammation-iron interactions in hematologic contexts.
If your company is interested in expert guidance for preclinical studies, data analysis, or scientific communications assistance, please send me a direct message to discuss potential collaborations.
I would love to hear your ideas!”
Read the full article here.
Article: TNFα signaling restores steady-state hematopoiesis in a TNFαKO mouse model of anemia of inflammation
Authors: Amaliris Guerra, Vania Lo Presti, Ding-Wen Chen, Ana Catarina Martins, Ariel Rivera, Nolan Hamilton, Pankja Sharma, Yelena Z. Ginzburg, Carlo Castruccio Castracani, Carla Casu, Ritama Gupta, Raffaella Gozzelino, Edward M. Behrens, Laura F. Bennett, Robert F. Paulson, Peter Kurre, Stefano Rivella
Stay updated on all scientific advances with Hemostasis Today.
-
May 30, 2026, 18:12Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
-
May 30, 2026, 18:11Alessandro Perrella: It is Not Only about “How High the CRP is”, but “in Which Patient” We are Measuring That Value
-
May 30, 2026, 18:11Jasper van Grunsven: Grateful for Our Rare Disease Team and the Commitment That Drives Our Mission
-
May 30, 2026, 18:10Open Registration for the 2026 Thrombosis Canada Annual Education Conference – Thrombosis Canada
-
May 30, 2026, 18:09Peter Zdziarski: Approval Does Not Mean NovoSeven is 100% Effective or Risk-Free in GT
-
May 30, 2026, 17:07Deepak Yadav: A Privilege to Talk on ESUS at CREST Stroke Conclave 2026
-
May 30, 2026, 16:59Syed A Rizvi: Medical Scoring Systems – Small Numbers, Big Clinical Decisions
-
May 30, 2026, 16:53Timothy “Tim” Sheehan: BNY Wealth Joins the Fight Against Blood Disorders In Support of Hemophilia of Georgia
-
May 30, 2026, 16:51Nouf Bahri: Anticoagulation Initiation for New-Onset Atrial Fibrillation in Critical Illness